Pheton Holdings Hits 52-Week Low Amid Major Shareholder Changes

Introduction

PHETON HOLDINGS LTD (NASDAQ: PTHL) is a China‐based holding company focused on healthcare solutions, primarily through its subsidiary Beijing Feitian Zhaoye Technology Co., Ltd. The firm develops and commercializes treatment planning software and related medical devices for brachytherapy, a form of radiotherapy that implants radioactive sources directly into cancerous tissue. As of July 30, 2025, PTHL shares traded at USD 0.8565, reflecting a 48.09 percent decline for the trading session, with a trading volume of 5,498,256 shares.

Corporate Structure and Governance

Incorporated in 2022 and headquartered in Beijing, Pheton operates with a workforce of ten employees. Its equity is divided into Class A and Class B ordinary shares (CUSIP G71399102), with each Class A share carrying one vote and each Class B share carrying twenty votes. As of April 22, 2025, there were 17,050,000 Class A shares and 7,668,000 Class B shares outstanding. Key Schedule 13G filings indicate the following shareholdings:

• ZJW (BVI) Ltd holds 7,668,000 Class A shares (53.8 percent of Class A).
• Ho Thiam Way holds 972,000 Class A shares (5.70 percent of Class A).
• ASEP Priharyanto holds 960,000 Class A shares (5.63 percent of Class A).

Brachytherapy by Nhia Moua

Recent Developments and News

On July 30, 2025, PTHL recorded a 52-week low of USD 0.60, down from a 52-week high of USD 32.00 reached on July 28, 2025. Earlier in 2025, the stock experienced notable volatility:

• On March 14, 2025, PTHL closed at USD 4.18, marking an 81.7 percent week-on-week gain from USD 2.30 on March 7, according to Yahoo Finance.
• Pheton disclosed its initial public offering plans to raise up to USD 11.25 million in GlobeNewswire filings dated September 5 and September 6, 2024, while also announcing product developments in medical auxiliary supplies.
• Schedule 13G disclosures on May 5, June 13, and June 16, 2025, updated major shareholders’ stakes, reflecting ongoing portfolio adjustments by institutional and individual investors.

Financial and Strategic Aspects

For the trailing twelve months ended June 30, 2025, Pheton reported:

• Revenue of USD 448,200, down 28.7 percent compared to 2023.
• Net loss of USD 660,588, indicating an increase in losses year-over-year.
• Gross margin of 85.04 percent and negative net margin of 147.39 percent.
• EBITDA of USD 770,300; EPS (TTM) of –0.05; ROE (TTM) of –20.35 percent.
• Cash balance of USD 6.16 million and a debt-to-equity ratio of 4.01 percent.
  With a market capitalization near USD 12 million and an enterprise value of USD 17.3 million, the company trades at approximately 46.3 times price-to-sales and 3.8 times price-to-book. Its strategic focus remains on expanding the adoption of its brachytherapy planning system (FTTPS) and complementary medical devices.

Market Position and Industry Context

Pheton operates in the micro-cap segment of healthcare technology, competing with providers of radiotherapy planning software and associated medical supplies. Its high software‐derived gross margins underscore the niche value of its treatment planning system, while the small revenue base and widening net losses highlight early-stage commercial challenges. Trading liquidity has varied, with a ten-day average volume around 3.41 million shares, and year-to-date share performance down approximately 82.6 percent as of July 30, 2025.

tl;dr

As of July 30, 2025, Pheton Holdings Ltd (PTHL) reached a 52-week low at USD 0.60 (with a 52-week high of USD 32.00 on July 28). The stock experienced a mid-March increase to USD 4.18 (March 14), which was reversed in subsequent months. Schedule 13G filings in May and June 2025 confirmed significant shareholdings by ZJW (BVI) Ltd (53.8 percent of Class A), Ho Thiam Way (5.7 percent), and ASEP Priharyanto (5.63 percent). Reporting TTM revenue of USD 448,200 and a net loss of USD 660,588, Pheton continues to focus on its FTTPS brachytherapy system while navigating low liquidity and ongoing shareholder restructurings.